A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
This article has no abstract
Epistemonikos ID: bd102059c72473c173258d8c9bfa82eb8f26829c
First added on: Jan 17, 2026